BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 39.1% in August

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 254,200 shares, a decline of 39.1% from the August 15th total of 417,200 shares. Approximately 1.7% of the company’s shares are sold short. Based on an average daily volume of 2,930,000 shares, the short-interest ratio is currently 0.1 days.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX traded down $0.07 during trading hours on Friday, reaching $0.56. 3,172,324 shares of the company were exchanged, compared to its average volume of 1,204,289. The firm has a market cap of $10.25 million, a price-to-earnings ratio of -0.45 and a beta of 1.31. The stock has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $1.60. BriaCell Therapeutics has a 52-week low of $0.52 and a 52-week high of $6.38.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its earnings results on Friday, June 14th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.66. On average, analysts predict that BriaCell Therapeutics will post -1.39 EPS for the current fiscal year.

Hedge Funds Weigh In On BriaCell Therapeutics

A number of large investors have recently modified their holdings of the company. National Bank of Canada FI grew its stake in shares of BriaCell Therapeutics by 200.0% in the fourth quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. K.J. Harrison & Partners Inc increased its stake in BriaCell Therapeutics by 7.8% during the 1st quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock worth $249,000 after buying an additional 6,329 shares during the period. Finally, Onyx Bridge Wealth Group LLC lifted its holdings in BriaCell Therapeutics by 66.7% in the 1st quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock worth $143,000 after buying an additional 20,000 shares in the last quarter. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of BriaCell Therapeutics in a research report on Wednesday.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.